ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Dose, Infection, and Disease Outcomes for Coronavirus Disease 2019 (COVID-19): A Review.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Virus-Mediated Self-Assembly of Functional Cyclodextrins for Antiviral Inhibition.Angewandte Chemie (International ed. in English) · 2026Article
- Article
- The role of vaccination and healthcare acquisition in respiratory failure during a COVID-19 outbreak in an acute hospital in Wales.Infection prevention in practice · 2025Article
- Longitudinal analysis of Covid-19 infection trends and in-hospital mortality across six pandemic waves in Tunisia.Archives of public health = Archives belges de sante publique · 2025Article
- Evaluation of the decontamination efficacy of a portable air cleaner using 275-nm UVC-LED radiation against airborne Coronavirus and Influenza virus.GMS hygiene and infection control · 2025Article
- Lung infection in orally inoculated SARS-CoV-2 hamsters.PloS one · 2025Article
- Building an Adverse Outcome Pathway network for COVID-19.Frontiers in systems biology · 2024Article
- Reducing Transmission of Airborne Respiratory Pathogens: A New Beginning as the COVID-19 Emergency Ends.Environmental health perspectives · 2024Review
- Demographic study of patients' mortality rate before and after the COVID-19 outbreak: A cross-sectional study.Health science reports · 2024Article
- A simplicial epidemic model for COVID-19 spread analysis.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Review
- A comparative NMR-based metabolomics study of lung parenchyma of severe COVID-19 patients.Frontiers in molecular biosciences · 2023Article
- The role of SARS-CoV-2 N protein in diagnosis and vaccination in the context of emerging variants: present status and prospects.Frontiers in microbiology · 2023Review
- Intrinsic host susceptibility among multiple species to intranasal SARS-CoV-2 identifies diverse virological, biodistribution and pathological outcomes.Scientific reports · 2022Article
- SARS-CoV-2 infection rate in Antananarivo frontline health care workers, Madagascar.Influenza and other respiratory viruses · 2022Article
- A population framework for predicting the proportion of people infected by the far-field airborne transmission of SARS-CoV-2 indoors.Building and environment · 2022Article
- Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases.Frontiers in microbiology · 2022Article
- Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here.BMC public health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
The relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dose, infection, and coronavirus disease 2019 (COVID-19) outcomes remains poorly understood. This review summarizes the existing literature regarding this issue, identifies gaps in current knowledge, and suggests opportunities for future research. In humans, host characteristics, including age, sex, comorbidities, smoking, and pregnancy, are associated with severe COVID-19. Similarly, in animals, host factors are strong determinants of disease severity, although most animal infection models manifest clinically with mild to moderate respiratory disease. The influence of variants of concern as it relates to infectious dose, consequence of overall pathogenicity, and disease outcome in dose-response remains unknown. Epidemiologic data suggest a dose-response relationship for infection contrasting with limited and inconsistent surrogate-based evidence between dose and disease severity. Recommendations include the design of future infection studies in animal models to investigate inoculating dose on outcomes and the use of better proxies for dose in human epidemiology studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.